BCL2L1 and acute lymphoblastic leukemia: By targeting BCL-XL and MCL-1, a combination of DHA and navitoclax interacted synergistically to kill mouse BCR-ABL+ B-ALL cells and suppress the progression of BCR-ABL+ B-ALL leukemia in vivo.